Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents

New England Journal of Medicine

Volumn 371, Issue 23, 2014, Pages 2155-2166

  Mauri, Laura ^a,b,c   Kereiakes, Dean J ^h   Yeh, Robert W ^a,c,d   Driscoll Shempp, Priscilla ^a   Cutlip, Donald E ^a,c,f   Steg, P Gabriel ^i,j,k   Normand, Sharon Lise T ^c,e   Braunwald, Eugene ^b,c   Wiviott, Stephen D ^b,c   Cohen, David J ^l   Holmes, David R ^m   Krucoff, Mitchell W ⁿ   Hermiller, James ^p   Dauerman, Harold L ^q   Simon, Daniel I ^r   Kandzari, David E ^s   Garratt, Kirk N ^t   Lee, David P ^u   Pow, Thomas K ^v   Lee, Peter Ver ^w   Rinaldi, Michael J ^o   Massaro, Joseph M ^a,g   more..

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^h Christ Hospital Heart and Vascular Center Lindner Research Center   (United States)

ⁱ BICHAT HOSPITAL   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^l UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^m MAYO CLINIC   (United States)

ⁿ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^o LEVINE CANCER INSTITUTE   (United States)

^p St Vincent s Heart Center of Indiana   (United States)

^q UNIVERSITY OF VERMONT   (United States)

^r UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^s PIEDMONT HEART INSTITUTE   (United States)

^t LENOX HILL HOSPITAL   (United States)

^u STANFORD UNIVERSITY   (United States)

^v Great Lakes Heart and Vascular Institute   (United States)

^w Eastern Maine Medical Center   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ADULT; ADVERSE OUTCOME; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELUTING CORONARY STENT; DRUG ELUTING STENT; DRUG SAFETY; EVEROLIMUS ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PACLITAXEL ELUTING STENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SIROLIMUS ELUTING STENT; STENT THROMBOSIS; TREATMENT DURATION; ZOTAROLIMUS ELUTING STENT; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED; MORTALITY; MYOCARDIAL ISCHEMIA; THROMBOSIS; TIME;

AGED; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; THROMBOSIS; TICLOPIDINE; TIME FACTORS;

EID: 84918772240     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1409312     Document Type: Article

References (38)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013; 127(1):e6-e245.
2. Erratum, Circulation 2013;127(23):e841.
3. Togni M, Balmer F, Pfiffner D, Maier W, Zeiher AM, Meier B. Percutaneous coronary interventions in Europe 1992- 2001. Eur Heart J 2004;25:1208-13.
4. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
5. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226-35.
6. Erratum, N Engl J Med 2011;365:2040.
7. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110: 1226-30.
8. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124(23):e574-e651.
9. Erratum, Circulation 2012;125(8):e142.
10. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:2541-619.
11. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68.
12. Valgimigli M, Campo G, Monti M, et al. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015-26.
13. Park S-J, Park D-W, Kim Y-H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-82.
14. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-22.
15. Collet JP, Silvain J, Barthélémy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014 July 15 (Epub ahead of print).
16. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the Dual Antiplatelet Therapy Study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-41.
17. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
18. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329: 673-82.
19. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123: 2736-47.
20. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-8.
21. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990;9:1447-54.
22. Little RJA, Rubin DB. Statistical anal-ysis with missing data. New York: Wiley, 1987.
23. Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimusand paclitaxel-eluting stents: 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 2011;58:19-25.
24. Wijns W, Steg PG, Mauri L, et al. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimuseluting stent: 4-year results of the PROTECT randomized trial. Eur Heart J 2014;35: 2812-20.
25. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
26. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-22.
27. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-9.
28. Erratum, JAMA 2008;299:2390.
29. The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817-25.
30. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
31. Errata, N Engl J Med 2001;345:1506, 1716.
32. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
33. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
34. Garg P, Galper BZ, Cohen DJ, Yeh RW, Mauri L. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare duration of dual antiplatelet therapy after drug-eluting stents. Am Heart J (http://www.ahjonline.com/article/S0002-8703(14)00661-9/abstract).
35. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimuseluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2014 September 12 (Epub ahead of print).
36. Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol 2012;59:1362-70.
37. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
38. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014;167:437-44.